Gameto received $10M in funding from ARPA-H to develop menopause-targeting therapies using a cell engineering platform.

Oct 24, 2024•about 1 year ago

Amount Raised

$10 Million

Bee CaveresearchBiotechnologyHealth Care

Description

Gameto has been awarded $10 million from the US Government’s ARPA-H initiative to advance its Ameno program, targeting menopause with innovative therapies. The funding will support the company's therapeutic development program, currently in preclinical stages, aimed at addressing critical challenges in women's health.

Company Information

Company

Gameto

Location

12117 Bee Caves Road

Bee Cave, Texas, United States

About

Gameto is a women's health biotechnology company advancing programs from a cell engineering platform developed with George Church's lab at Harvard Medical School. Founded by Dr. Dina Radenkovic, a medical doctor-turned-entrepreneur, and Martin Varsavsky, founder of one of North America's largest fertility clinic network, Inception Prelude, Gameto has raised $127 million from leading investors to develop therapies that address fertility, menopause, and women's and family health. The company's lead program, Fertilo, is currently in Phase 3 clinical trials.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Gameto received $10M in funding from ARPA-H to develop menopause-targeting therapies using a cell engineering platform.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information